CERN physicists report first observations of matter-antimatter imbalance in subatomic particle
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Physicists at CERN have reported the first observations of matter-antimatter imbalance in a subatomic particle 'baryon', offering clues as to why matter dominates in the universe.Particles of antimatter -- called 'antiparticles' -- have the same mass as particles of matter but an opposite charge.According to particle physics models, matter and antimatter should have been created in equal amounts following the Big Bang. However, research indicates a significant imbalance, with matter dominating over antimatter. Understanding why the universe favours matter is one of the most profound questions in physics.The Standard Model of particle physics -- currently the leading model, as it is said to provide the best explanation about the fundamental nature of matter -- predicts that matter and antimatter behave differently.The model theoretically predicts that when a particle is replaced with an antiparticle and its position in space is mirrored, the laws of physics are violated. This violation is referred to as 'charge-parity' (CP) violation.Previously, CP violation was observed in mesons - a type of subatomic particle that weighs between an electron and a proton. These observations were first documented over 60 years ago.In a recent paper published in the journal Nature, researchers from the Large Hadron Collider beauty (LHCb) Collaboration at the European Organization for Nuclear Research (CERN), Switzerland, have, for the first time, observed this violation in baryons , of which protons and neutrons are types.Specifically, the violation was noted in a baryon that decayed into a proton and mesons.The authors of the study stated, "These observations demonstrate the different behaviours of baryons and antibaryons." This finding is significant as baryons constitute most of the matter in the observable universe."This discovery opens a new path in the search for physics beyond the Standard Model," the team wrote.For the study, the researchers analysed data collected from proton-proton collisions at the Large Hadron Collider -- the world's largest and most powerful particle accelerator located at CERN."The ( charge-parity violation ) reveals a difference in behaviour between baryonic matter and antimatter," the authors wrote."While such a violation was predicted and does not resolve the Big Bang matter-antimatter imbalance, finding out the details of this violation experimentally will offer important clues, opening up opportunities for further theoretical and experimental studies of the nature of (charge-parity) violation," they added.It is said that matter and antimatter can interact and destroy each other in a process called 'annihilation', converting all the mass into 'radiant energy' -- which is energy that exists in the absence of matter.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
CERN discovery could hint at why universe is made of matter, not antimatter
Why didn't the universe annihilate itself moments after the big bang? A new finding at Cern on the French-Swiss border brings us closer to answering this fundamental question about why matter dominates over its opposite – antimatter. Much of what we see in everyday life is made up of matter. But antimatter exists in much smaller quantities. Matter and antimatter are almost direct opposites. Matter particles have an antimatter counterpart that has the same mass, but the opposite electric charge. For example, the matter proton particle is partnered by the antimatter antiproton, while the matter electron is partnered by the antimatter positron. However, the symmetry in behaviour between matter and antimatter is not perfect. In a paper published this week in Nature, the team working on an experiment at Cern, called LHCb, has reported that it has discovered differences in the rate at which matter particles called baryons decay relative to the rate of their antimatter counterparts. In particle physics, decay refers to the process where unstable subatomic particles transform into two or more lighter, more stable particles. According to cosmological models, equal amounts of matter and antimatter were made in the big bang. If matter and antimatter particles come in contact, they annihilate one another, leaving behind pure energy. With this in mind, it's a wonder that the universe doesn't consist only of leftover energy from this annihilation process. However, astronomical observations show that there is now a negligible amount of antimatter in the universe compared to the amount of matter. We therefore know that matter and antimatter must behave differently, such that the antimatter has disappeared while the matter has not. Understanding what causes this difference in behaviour between matter and antimatter is a key unanswered question. While there are differences between matter and antimatter in our best theory of fundamental quantum physics, the standard model, these differences are far too small to explain where all the antimatter has gone. So we know there must be additional fundamental particles that we haven't found yet, or effects beyond those described in the standard model. These would give rise to large enough differences in the behaviour of matter and antimatter for our universe to exist in its current form. Revealing new particles Highly precise measurements of the differences between matter and antimatter are a key topic of research because they have the potential to be influenced by and reveal these new fundamental particles, helping us discover the physics that led to the universe we live in today. Differences between matter and antimatter have previously been observed in the behaviour of another type of particle, mesons, which are made of a quark and an antiquark. There are also hints of differences in how the matter and antimatter versions of a further type of particle, the neutrino, behave as they travel. The new measurement from LHCb has found differences between baryons and antibaryons, which are made of three quarks and three antiquarks respectively. Significantly, baryons make up most of the known matter in our universe, and this is the first time that we have observed differences between matter and antimatter in this group of particles. The LHCb experiment at the Large Hadron Collider is designed to make highly precise measurements of differences in the behaviour of matter and antimatter. The experiment is operated by an international collaboration of scientists, made up of over 1,800 people based in 24 countries. In order to achieve the new result, the LHCb team studied over 80,000 baryons ('lambda-b' baryons, which are made up of a beauty quark, an up quark and a down quark) and their antimatter counterparts. Crucially, we found that these baryons decay to specific subatomic particles (a proton, a kaon and two pions) slightly more frequently – 5 per cent more often – than the rate at which the same process happens with antiparticles. While small, this difference is statistically significant enough to be the first observation of differences in behaviour between baryon and antibaryon decays. To date, all measurements of matter-antimatter differences have been consistent with the small level present in the standard model. While the new measurement from LHCb is also in line with this theory, it is a major step forward. We have now seen differences in the behaviour of matter and antimatter in the group of particles that dominate the known matter of the universe. It's a potential step in the direction of understanding why that situation came to be after the big bang. With the current and forthcoming data runs of LHCb we will be able to study these differences forensically, and, we hope, tease out any sign of new fundamental particles that might be present.
Economic Times
a day ago
- Economic Times
Cancer cure found? Scientists create a new mRNA vaccine that triggers strong anticancer immune response against tumours
A new approach to cancer treatment Towards a universal cancer vaccine Live Events Building on past research (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel In a major development in cancer research , scientists at the University of Florida have created an experimental mRNA vaccine that stimulates the immune system to attack tumours. According to a study published in Nature Biomedical Engineering, the vaccine, when used alongside immune checkpoint inhibitors, produced a strong antitumor effect in vaccine does not target specific cancer proteins. Instead, it activates the immune system in the same way it would respond to a virus. Researchers found that the vaccine increased the levels of a protein called PD-L1 within tumours, making them more sensitive to Elias Sayour, a paediatric oncologist at UF Health and the lead researcher, said this development could lead to a new form of cancer treatment that does not rely entirely on surgery, radiation, or chemotherapy. The research was supported by the National Institutes of Health and other leading institutions.'This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus – so long as it is an mRNA vaccine – could lead to tumor-specific effects,' said Sayour, who is also the principal investigator at the RNA Engineering Laboratory at UF's Preston A. Wells Jr. Center for Brain Tumor added, 'This finding is a proof of concept that these vaccines potentially could be commercialised as universal cancer vaccine s to sensitise the immune system against a patient's individual tumor.'The research challenges the two current approaches in cancer-vaccine development: targeting common proteins found in cancer patients or customising a vaccine for each patient. This study suggests a third path that focuses on stimulating a broad immune response.'This study suggests a third emerging paradigm,' said Duane Mitchell, MD, PhD, a co-author of the paper. 'What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine .'Sayour has spent more than eight years developing mRNA-based cancer vaccines using lipid nanoparticles. These vaccines work by delivering messenger RNA (mRNA), a molecule that instructs cells to make specific proteins, into the body to prompt an immune year, Sayour's lab conducted a human trial using a personalised mRNA vaccine made from a patient's own tumour cells. The treatment quickly activated the immune system to fight glioblastoma, a deadly brain cancer. The new study builds on that work by testing a generalised mRNA vaccine, not specific to any virus or cancer formulation of this new vaccine is similar to the technology used in COVID-19 vaccines but is designed to prompt a general immune response rather than target a specific protein like the COVID spike the vaccine shows similar results in future human studies, it could lead to a universal tool in the fight against cancer.
Time of India
a day ago
- Time of India
Cancer cure found? Scientists create a new mRNA vaccine that triggers strong anticancer immune response against tumours
In a major development in cancer research , scientists at the University of Florida have created an experimental mRNA vaccine that stimulates the immune system to attack tumours. According to a study published in Nature Biomedical Engineering, the vaccine, when used alongside immune checkpoint inhibitors, produced a strong antitumor effect in mice. The vaccine does not target specific cancer proteins. Instead, it activates the immune system in the same way it would respond to a virus. Researchers found that the vaccine increased the levels of a protein called PD-L1 within tumours, making them more sensitive to immunotherapy. Explore courses from Top Institutes in Select a Course Category Public Policy CXO PGDM Others Leadership MCA Data Science Management Product Management Degree Design Thinking Data Science Cybersecurity others Finance Digital Marketing Technology Artificial Intelligence Healthcare MBA Data Analytics Project Management Operations Management healthcare Skills you'll gain: Duration: 12 Months IIM Calcutta Executive Programme in Public Policy and Management Starts on undefined Get Details Skills you'll gain: Economics for Public Policy Making Quantitative Techniques Public & Project Finance Law, Health & Urban Development Policy Duration: 12 Months IIM Kozhikode Professional Certificate Programme in Public Policy Management Starts on Mar 3, 2024 Get Details A new approach to cancer treatment Dr. Elias Sayour, a paediatric oncologist at UF Health and the lead researcher, said this development could lead to a new form of cancer treatment that does not rely entirely on surgery, radiation, or chemotherapy. The research was supported by the National Institutes of Health and other leading institutions. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo 'This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus – so long as it is an mRNA vaccine – could lead to tumor-specific effects,' said Sayour, who is also the principal investigator at the RNA Engineering Laboratory at UF's Preston A. Wells Jr. Center for Brain Tumor Therapy. Towards a universal cancer vaccine Sayour added, 'This finding is a proof of concept that these vaccines potentially could be commercialised as universal cancer vaccine s to sensitise the immune system against a patient's individual tumor.' Live Events The research challenges the two current approaches in cancer-vaccine development: targeting common proteins found in cancer patients or customising a vaccine for each patient. This study suggests a third path that focuses on stimulating a broad immune response. 'This study suggests a third emerging paradigm,' said Duane Mitchell, MD, PhD, a co-author of the paper. 'What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine .' Building on past research Sayour has spent more than eight years developing mRNA-based cancer vaccines using lipid nanoparticles. These vaccines work by delivering messenger RNA (mRNA), a molecule that instructs cells to make specific proteins, into the body to prompt an immune reaction. Last year, Sayour's lab conducted a human trial using a personalised mRNA vaccine made from a patient's own tumour cells. The treatment quickly activated the immune system to fight glioblastoma, a deadly brain cancer. The new study builds on that work by testing a generalised mRNA vaccine, not specific to any virus or cancer mutation. The formulation of this new vaccine is similar to the technology used in COVID-19 vaccines but is designed to prompt a general immune response rather than target a specific protein like the COVID spike protein. If the vaccine shows similar results in future human studies, it could lead to a universal tool in the fight against cancer.
